Intarcia Gets Its Hearing: FDA Panel To Weigh Nonapproval Of Diabetes Drug/Device Combo In September

 
• By Sue Sutter

Since the Center for Drug Evaluation and Research is conducting the single-day hearing on the type 2 diabetes treatment ITCA 650 under its usual process for advisory committee meetings, it denied Intarcia’s requests for input on adding ad hoc members and extended presentation time.

Boxing gloves
FDA and Intarcia will duke it out at an Endocrinologic and Metabolic Drugs Advisory Committee meeting on 21 September. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers